UK govt relents over NHS reform unease - an opportunity for industry
This article was originally published in Clinica
Unease at the UK government’s widely-opposed planned reforms of the NHS came to a head yesterday with the announcement of a pause in the passage of the Health and Social Care Bill that enshrines the reforms.
You may also be interested in...
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.